However, gastrointestinal adverse events -- primarily nausea, vomiting, diarrhea, and constipation -- occurred in 80.9-89.7% ...

AI company unlocking causal human biology, today presented new preclinical data from its metabolic dysfunction-associated steatohepatitis (MASH) therapeutic development program during a podium ...

MTRX31 led to a highly significant decrease in fat mass after two-months chronic dosing in a preclinical diet-induced obesity mouse model ...

In a pre‑specified sub study, survodutide achieved a reduction of up to 34% in visceral fat, while lean mass accounted for no ...

Boehringer’s Phase III data show survodutide cuts visceral & liver fat and drives weight loss, boosting its obesity/MASLD ...

Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results ...

The Knicks’ practice-day media session at Madison Square Garden welcomed two unexpected guests on Sunday: New York City ...

Boehringer Ingelheim’s survodutide phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing ...

Weight loss and reduction of fat deposits in multiple organs (ectopic fat) was observed with MTRX31, comparable to combinations of current modalities (GLP-1RA, GIP, ActR) while improving circulating ...

In an MRI substudy, the researchers found that survodutide improved body composition and liver fat content, with a 34% ...

The odes to the home team come from pioneers who uplifted the genre (Rakim), veteran superstars (Busta Rhymes), independent ...